公开(公告)号：US20230255929A1

公开(公告)日：2023-08-17

申请号：US18138351

申请日：2023-04-24

Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

Inventor： Mark G. Frattini ,  Hakim Djaballah ,  Thomas J. Kelly

IPC: A61K31/365 ,  A61K31/122 ,  C09B13/02 ,  C09B61/00 ,  C12Q1/6886 ,  A61K31/352 ,  A61N5/10 ,  C07D493/08 ,  C07D493/18 ,  A61K9/00

CPC classification number: A61K31/365 ,  A61K31/122 ,  C09B13/02 ,  C09B61/00 ,  C12Q1/6886 ,  A61K31/352 ,  A61N5/10 ,  C07D493/08 ,  C07D493/18 ,  A61K9/0019 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B):




or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.

公开(公告)号：US11045446B2

公开(公告)日：2021-06-29

申请号：US16189780

申请日：2018-11-13

Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

Inventor： Mark G. Frattini ,  Hakim Djaballah ,  Thomas J. Kelly

IPC: C07D493/08 ,  C07D493/18 ,  A61K31/122 ,  A61K31/352 ,  A61K31/365 ,  C09B13/02 ,  C09B61/00 ,  C12Q1/6886 ,  A61N5/10 ,  A61K9/00

Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.

公开(公告)号：US2553046A

公开(公告)日：1951-05-15

申请号：US74319547

申请日：1947-04-22

Applicant: SANDOZ LTD

Inventor： VALENTIN KARTASCHOFF

IPC: C09B13/02

CPC classification number: C09B13/02

公开(公告)号：US1991885A

公开(公告)日：1935-02-19

申请号：US37987429

申请日：1929-07-20

Applicant: CELANESE CORP

Inventor： HOLLAND ELLIS GEORGE ,  CHARLES OLPIN HENRY ,  WILLIAM KIRK ERNEST

IPC: C09B13/02

CPC classification number: C09B13/02

公开(公告)号：US20250090495A1

公开(公告)日：2025-03-20

申请号：US18969747

申请日：2024-12-05

Applicant: Lin Bioscience, Inc.

Inventor： Tom LIN ,  Irene WANG ,  Mark G. Frattini ,  Hakim DJABALLAH ,  Thomas J. Kelly

IPC: A61K31/365 ,  A61K9/00 ,  A61K31/122 ,  A61K31/352 ,  A61N5/10 ,  C07D493/08 ,  C07D493/18 ,  C09B13/02 ,  C09B61/00 ,  C12Q1/6886

Abstract: The present invention provides a method of treatment and composition for CDC7 inhibitor combinational therapy for treatment of proliferative diseases. In an embodiment, the composition of the present invention comprises a therapeutically effective amount of a combination of a CDC7 inhibitor of the present invention or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents. In an embodiment, the CFC7 inhibitor comprises granaticin B. In an embodiment, the antneoplastic agent comprises azacitidine and venetoclax. The present invention further provides a method of treatment comprising the step of administration to a subject suffering from proliferative disease of any embodiment of the composition of the present invention.

公开(公告)号：US10338372B2

公开(公告)日：2019-07-02

申请号：US14310484

申请日：2014-06-20

Applicant: Amazon Technologies, Inc.

Inventor： Robin Leguijt ,  Jurriën Mans ,  Sukhdip Sandhu

IPC: G02B26/00 ,  C09B1/28 ,  C09B29/00 ,  C09B29/08 ,  C09B29/36 ,  C09B31/043 ,  C07F7/30 ,  C07F7/08 ,  C09B13/02 ,  C09B29/01 ,  C09B31/14 ,  C09B31/18 ,  C09B55/00 ,  C09B56/08 ,  C09B1/26

Abstract: Electrowetting apparatus including at least one compound selected from the group consisting of: wherein each of R1, R2, R3 and R4 is independently an alkyl group. In examples a fluid includes a dye compound selected from:

公开(公告)号：US10123992B2

公开(公告)日：2018-11-13

申请号：US15728609

申请日：2017-10-10

Applicant: Sloan-Kettering Institute for Cancer Research

Inventor： Mark G. Frattini ,  Hakim Djaballah ,  Thomas J. Kelly

IPC: A61K31/365 ,  A61K9/00 ,  A61N5/10 ,  A61K31/122 ,  A61K31/352 ,  C07D493/08 ,  C07D493/18 ,  C09B13/02 ,  C09B61/00 ,  C12Q1/6886

Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.

公开(公告)号：US5108903A

公开(公告)日：1992-04-28

申请号：US215140

申请日：1988-07-05

Applicant: Jared B. Mooberry

Inventor： Jared B. Mooberry

IPC: G01N31/22 ,  C07D279/22 ,  C09B13/02 ,  C09B19/00 ,  C09B21/00 ,  C09B29/00 ,  C09B53/00 ,  C09B55/00 ,  C09B62/78 ,  C09B62/825 ,  C12Q1/04 ,  C12Q1/26 ,  G01N33/52

CPC classification number: C09B13/02 ,  C12Q1/04 ,  G01N33/52 ,  C12Q2304/20

Abstract: Certain reducible compounds are useful in analytical compositions, elements and methods, for example for the detection of bacterial cells. These compounds comprise a moiety which provides a leuco dye upon reduction. This lecuo dye can then be oxidized with additional molecules of reducible compound in order to provide a detectable dye. Thus, these reducible compounds are considered bioamplifiers from which a multiplicity of dye molecules can be provided from a single reducible compound molecule. Structurally, the reducible compounds are quinones having suitable substituents which promote varying amounts of leuco dye release at physiological pH.

公开(公告)号：US4499004A

公开(公告)日：1985-02-12

申请号：US462153

申请日：1983-01-28

Applicant: Gunther Haas ,  Georg Weber

Inventor： Gunther Haas ,  Georg Weber

IPC: C09B13/00 ,  C09B13/02 ,  C09K19/60 ,  G02F1/137 ,  G02F1/13 ,  C09K3/34

CPC classification number: C09B13/02 ,  C09K19/60

Abstract: A new liquid crystal dielectric contains at least one dyestuff of formula I ##STR1## wherein R.sup.1 and R.sup.2 are identical or different and each is alkyl or alkoxy each of 3 to 8 C atoms or a group Z--Y--, or one of R.sup.1 and R.sup.2 can also be hydrogen, methyl, ethyl, methoxy or ethoxy; Z is R--Ph--, R--Ph--Ph--, R--Cy--, R--Cy--Cy--, R--Cy--Ph-- or R--Ph--Cy--; Ph is 1,4-phenylene; Cy is 1,4-cyclohexylene; Y is --CH.sub.2 --, --O--, --S--, --NH--, --CH.sub.2 CH.sub.2 --, --CH.sub.2 --O--, --CH.sub.2 --S--, --CH.sub.2 --NH--, or a direct bond; and R is hydrogen or alkyl or alkoxy, each of 1-8 C atoms.

Abstract translation: 一种新的液晶电介质包含至少一种式I的染料，其中R 1和R 2相同或不同，并且各自为3至8个C原子的烷基或烷氧基或ZY-基团，或者R 1和R 2中的一个 也可以是氢，甲基，乙基，甲氧基或乙氧基; Z是R-Ph + 13，R-Ph-Ph-，R-Cy-，R-Cy-Cy-，R- Cy-Ph-或R-Ph-Cy-; Ph为1,4-亚苯基; Cy是1,4-亚环己基; Y是-CH 2 - ， - O - ， - S - ， - NH - ， - CH 2 CH 2 - ， - CH 2 -O-，-CH 2 -S-，-CH 2 -NH-或直接键; 且R为氢或烷基或烷氧基，各为1-8个C原子。

公开(公告)号：US2275741A

公开(公告)日：1942-03-10

申请号：US30845739

申请日：1939-12-09

Applicant: EASTMAN KODAK CO

Inventor： DICKEY JOSEPH B ,  MCNALLY JAMES G

IPC: C09B13/02

CPC classification number: C09B13/02 ,  Y10S8/921